VivoSeq
Oncology

Squamous Cell Cancer

0

Pipeline Programs↗

6

Active Trials↗

2

Companies Involved↗

Squamous Cell Cancer is an early-stage landscape with 0 programs across 2 companies. The most active players are Gynecologic Oncology Group, Galera Therapeutics, Inc..

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

75/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

G

Gynecologic Oncology Group

0 programs

PreclinicalG

Galera Therapeutics, Inc.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

20

clinical trials

Completed9 · 45%
Terminated3 · 15%
Active, not recruiting3 · 15%
Recruiting2 · 10%
Unknown status2 · 10%
Not yet recruiting1 · 5%

Clinical Trials

Trial Activity

20 trials

Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer
Recruiting·EEmory University·Phase 1·NCT04428671·20 enrolled
Microneedle Array Plus Doxorubicin in Cutaneous Squamous Cell Cancer (cSCC)
Recruiting·FFalo, Louis, MD·Phase 1/2·NCT05377905·48 enrolled
Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT03565783·44 enrolled
OSI-774/Cisplatin/Taxotere in Head & Neck Squamous Cell Cancer
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT00076310·50 enrolled
Avelumab With or Without Cetuximab in Treating Patients With Advanced Skin Squamous Cell Cancer
Active, not recruiting·Alliance for Clinical Trials in Oncology·Phase 2·NCT03944941·60 enrolled
Clinical Trial Comparing Induction Treatment With EGFR-ADC MRG003 Alone or in Combination With the Anti PD1 Pucotenlimab, Followed by Radiochemotherapy in Locally Advanced Squamous Cell Cancers of the Head and Neck
Not yet recruiting·GGroupe Oncologie Radiotherapie Tete et Cou·Phase 2·NCT06959108·106 enrolled
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
Completed·—·Phase 1·NCT02113878·23 enrolled
Study of TVEC in Patients With Cutaneous Squamous Cell Cancer
Completed·UUniversity of Arizona·Phase 2·NCT03714828·11 enrolled
Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and Neck
Completed·YYale University·Phase 2·NCT02979977·50 enrolled
GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer
Completed·WWashington University School of Medicine·Phase 2·NCT01553851·20 enrolled
A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck
Completed·GGalera Therapeutics, Inc.·Phase 1·NCT01921426·30 enrolled
Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer
Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT02784288·40 enrolled
TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck
Completed·UUniversity of Washington·Phase 1·NCT01334177·13 enrolled
Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer
Completed·MM.D. Anderson Cancer Center·Phase 1·NCT03144778·39 enrolled
Preoperative TPF Chemotherapy in Molecularly Selected Locally Advanced Resectable Oral Cavity Squamous Cell Cancer
Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT01914900·14 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)